---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041889"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:04:29.044948+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain

## Summary
- Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.
- Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.
- Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.
- Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.
- Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses.

## SEC filing metadata
- accession: 0000950170-23-041889
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/0000950170-23-041889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/revb-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041889
- JSON: https://secwatch.observer/filing/0000950170-23-041889.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041889.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported the three and six months ended June 30, 2023 results: net income net loss of $1.4 million, or $0.25 basic and diluted net loss per share, EPS $0.25 basic and diluted net loss per share.
  - Period: the three and six months ended June 30, 2023
  - Net income: net loss of $1.4 million, or $0.25 basic and diluted net loss per share
  - EPS: $0.25 basic and diluted net loss per share
  - Result: reported results
  source text: On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023041889/0000950170-23-041889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.